Wedbush Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $118
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Wedbush analyst Yun Zhong maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $112 to $118.
Wedbush analyst Yun Zhong maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $112 to $118.